Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer
- Author(s)
- Lau, DK; Collin, JP; Mariadason, JM;
- Details
- Publication Year 2024-05-17,Volume 12,Issue #5,Page 1117
- Journal Title
- Biomedicines
- Publication Type
- Review
- Abstract
- Recent advances in the treatment of gastric cancer (GC) with chemotherapy, immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some improvement in survival outcomes; however, metastatic GC remains a lethal malignancy and amongst the leading causes of cancer-related mortality worldwide. Importantly, the ongoing molecular characterisation of GCs continues to uncover potentially actionable molecular targets. Among these, aberrant FGFR2-driven signalling, predominantly arising from FGFR2 amplification, occurs in approximately 3-11% of GCs. However, whilst several inhibitors of FGFR have been clinically tested to-date, there are currently no approved FGFR-directed therapies for GC. In this review, we summarise the significance of FGFR2 as an actionable therapeutic target in GC, examine the recent pre-clinical and clinical data supporting the use of small-molecule inhibitors, antibody-based therapies, as well as novel approaches such as proteolysis-targeting chimeras (PROTACs) for targeting FGFR2 in these tumours, and discuss the ongoing challenges and opportunities associated with their clinical development.
- Publisher
- MDPI
- Keywords
- Fgfr2; gastric cancer; monoclonal antibodies; targeted therapies
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.3390/biomedicines12051117
- Open Access at Publisher's Site
https://doi.org/10.3390/biomedicines12051117- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-11 06:58:36
Last Modified: 2024-07-11 07:07:57